RxDoctor Payments Data

Sean Horrigan, DO

Internal Medicine · Worcester, MANPI 1821140351

Payments from drug & device makers

$1,835in general payments, 2019–2025

Across 69 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$655
  • Sanofi$283
  • Lilly USA, LLC$247
  • Johnson & Johnson$132
  • Eisai Inc.$122
  • Lundbeck LLC$98
  • plus $299 from 8 others

What the payments were for

  • Food & beverage$1,835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,835 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$303,015
Medicare patients
1,212
Services billed
6,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate13$91,000
Nurtec OdtRimegepant Sulfate53$82,241
Teriflunomide12$52,657
Rivastigmine96$28,457
UbrelvyUbrogepant19$26,961
BriviactBrivaracetam18$26,053
Memantine Hcl365$19,548
ExelonRivastigmine16$16,246
Emgality PenGalcanezumab-Gnlm14$15,700
Memantine Hcl ErMemantine Hcl121$15,421
Emgality SyringeGalcanezumab-Gnlm15$10,076
Carbidopa-LevodopaCarbidopa/Levodopa251$9,571
Donepezil Hcl693$7,692
Levetiracetam ErLevetiracetam93$6,586
RivastigmineRivastigmine Tartrate46$6,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$655$26,96119 claims
NovartisExelon$73$16,24616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →